Clin2
NCT06998875Possibly a fitRecruiting

Study of avastin and tofacitinib for skin amyloidosis

Primary Cutaneous Amyloidosis

Part of Skin clinical trials.

This trial looks at people with primary cutaneous amyloidosis who have been treated with Avastin Capsules or Tofacitinib Citrate. It aims to track how well these medications work and if they are safe over time.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
56 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older and do not have hepatitis B, tuberculosis, or other major health conditions.
  • You have been diagnosed with primary cutaneous amyloidosis, macular amyloidosis, or lichen amyloidosis.
  • You have visited the clinic for this condition at least 4 times.
  • Your medical records show you have taken Avastin Capsules and/or Tofacitinib Citrate.
  • You are not currently using other immune-suppressing drugs or biologics (like steroids or methotrexate).
  • You do not have nodular or systemic amyloidosis.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07143864Not yet recruiting
Stapokibart for primary cutaneous amyloidosis

This study tests an investigational injection (Stapokibart) for people with moderate to severe primary cutaneous amyloidosis, a condition that causes itchy, thickened skin. It aims to see if the drug can safely reduce symptoms in people who haven't gotten enough relief from standard treatments.

NCT06698822Recruiting· Phase 2
Tofacitinib cream for early-stage cutaneous T-cell lymphoma

This trial is testing a cream called tofacitinib (a type of medicine that helps calm the immune system) for people with early-stage cutaneous T-cell lymphoma (CTCL). The goal is to see if it helps shrink or control the skin lesions safely.

Houston, Texas
NCT06689982Not yet recruiting· Early Phase 1
Tofacitinib for people with ALS and a specific immune profile

This study tests a drug called tofacitinib, which calms the immune system, in people with ALS. It aims to see if it can slow the disease by blocking an overactive immune response linked to certain genetic patterns.

Beijing
NCT06393972Not yet recruiting· Phase 2
Tofacitinib for steroid-resistant heart inflammation from immunotherapy

This trial tests if the drug tofacitinib can help people whose heart inflammation from cancer immunotherapy (called ICI-related myocarditis) does not improve with steroids. If you have this condition, this study may offer a new treatment option.

NCT06974877Recruiting· Phase 1
PET/CT Imaging for Amyloid in CAPS on Anakinra

This trial uses a special PET/CT scan to see if a radioactive tracer can measure changes in amyloid buildup in people with CAPS who have developed a skin reaction to anakinra. It may help doctors understand how the disease is affecting your organs.

Bethesda, Maryland
NCT06625450Not yet recruiting· Phase 4
Tofacitinib alone or with mesalamine for ulcerative colitis

This study tests whether taking tofacitinib alone works as well as taking tofacitinib with mesalamine for people with ulcerative colitis who are already in remission. It aims to see if one medication can be stopped without causing a flare-up.

Hear when a new Primary Cutaneous Amyloidosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.